Opinion

Video

Clinical Utility of the Modified Friedreich Ataxia Rating Scale

Key Takeaways

  • mFARS is designed to assess Friedreich Ataxia progression in clinical trials, focusing on motor function and disease severity.
  • Its complexity and time requirements may limit routine use in everyday clinical practice.
SHOW MORE

Sub Subramony, M.D., discusses how the modified Friedreich Ataxia Rating Scale (mFARS) is valuable for monitoring disease progression in clinical trials and its applicability in everyday clinical practice for assessing patient status.

Related Videos
Justin Oldham, MD, MS, an expert on IPF
Justin Oldham, MD, MS, an expert on IPF
Justin Oldham, MD, MS, an expert on IPF
Justin Oldham, MD, MS, an expert on IPF
Susan Perlman, MD, an expert on Friedreich's ataxia
1 KOL is featured in this series.
Justin Oldham, MD, MS, an expert on IPF
Justin Oldham, MD, MS, an expert on IPF
Susan Perlman, MD, an expert on Friedreich's ataxia
Susan Perlman, MD, an expert on Friedreich's ataxia
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo